We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New Test Developed For Early Detection Of Lyme Disease

By LabMedica International staff writers
Posted on 12 May 2016
A new test for early detection of Lyme disease (borreliosis) is being developed and this will improve the ability to detect an active infection more easily than before so that healthy people with Lyme disease antibodies in their blood do not receive unnecessary antibiotic treatment and so that appropriate treatments can be initiated at an early stage.

The current test is only able to analyze part of the human immune system, namely the B-cells but not the T-cells, which are needed as helper cells to fight the infection and whose activity indicates the presence of an infection. More...
The antibody tests that are currently available only provide a reliable result three to four weeks after infection has occurred.

Immunologists at the Medical University of Vienna (Austria) are developing the world's first point-of-care test, which could be used to detect an active infection so that patients could start the appropriate treatment. The test, which is known as the "Ixodes Kit" should be in clinical use in the autumn of 2016, said the scientists, speaking on the occasion of World Immunology Day 2016. Ixodes is the scientific name for hard-bodied ticks that transmit the disease.

Lyme disease is particularly common in Central Europe and in the Scandinavian countries. As a result of climate change, its area of spread is continuously moving northwards. Tick activity is starting earlier and earlier. In Austria itself, they currently have the best climate for ticks. Every year around 70,000 people in Austria develop Lyme disease after being bitten by a deer tick. Approximately one in every four ticks carries Lyme disease. So-called erythema migrans is a sure sign of infection with tick-borne Lyme disease. However, this only occurs in around one third of patients. If the bacterial infection is not detected in good time it can lead to serious problems such as joint inflammation and even very painful infections of the nerve roots resulting in paralysis or memory loss.

Hannes Stockinger, PhD, a professor and Head of the Institute for Hygiene and Applied Immunology, said, “Unfortunately, the current standard laboratory test is often unable to detect Lyme disease at an early stage of the infection. On top of that, the current test often interprets a mere antibody reaction as an infection and people are treated with antibiotics unnecessarily, because the infection is way in the past or is already completely resolved.” In Europe and Asia, the bacteria Borrelia afzelii and Borrelia garinii are the causes of Lyme disease.

Related Links:
Medical University of Vienna


Gold Member
Veterinary Hematology Analyzer
Exigo H400
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated PCR Setup
ESTREAM
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: How the predictive test works (Photo courtesy of QMUL)

World’s First Clinical Test Predicts Best Rheumatoid Arthritis Treatment

Rheumatoid arthritis (RA) is a chronic condition affecting 1 in 100 people in the UK today, causing the immune system to attack its joints. Unlike osteoarthritis, which is caused by wear and tear, RA can... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.